Trials / Completed
CompletedNCT03290560
Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (actual)
- Sponsor
- DiaMedica Therapeutics Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic stroke patients. The study will be randomized, placebo controlled at multiple centers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Recombinant human tissue kallikrein | Recombinant human tissue kallikrein |
| OTHER | Placebo | Placebo Comparator: Phosphate buffered saline |
Timeline
- Start date
- 2018-01-19
- Primary completion
- 2020-01-23
- Completion
- 2020-01-23
- First posted
- 2017-09-25
- Last updated
- 2022-03-31
Locations
12 sites across 1 country: Australia
Source: ClinicalTrials.gov record NCT03290560. Inclusion in this directory is not an endorsement.